Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Infect Immun. 2014 Jun;82(6):2485-503. doi: 10.1128/IAI.01595-13. Epub 2014 Mar 31.
Currently, there is no FDA-approved vaccine against Yersinia pestis, the causative agent of bubonic and pneumonic plague. Since both humoral immunity and cell-mediated immunity are essential in providing the host with protection against plague, we developed a live-attenuated vaccine strain by deleting the Braun lipoprotein (lpp) and plasminogen-activating protease (pla) genes from Y. pestis CO92. The Δlpp Δpla double isogenic mutant was highly attenuated in evoking both bubonic and pneumonic plague in a mouse model. Further, animals immunized with the mutant by either the intranasal or the subcutaneous route were significantly protected from developing subsequent pneumonic plague. In mice, the mutant poorly disseminated to peripheral organs and the production of proinflammatory cytokines concurrently decreased. Histopathologically, reduced damage to the lungs and livers of mice infected with the Δlpp Δpla double mutant compared to the level of damage in wild-type (WT) CO92-challenged animals was observed. The Δlpp Δpla mutant-immunized mice elicited a humoral immune response to the WT bacterium, as well as to CO92-specific antigens. Moreover, T cells from mutant-immunized animals exhibited significantly higher proliferative responses, when stimulated ex vivo with heat-killed WT CO92 antigens, than mice immunized with the same sublethal dose of WT CO92. Likewise, T cells from the mutant-immunized mice produced more gamma interferon (IFN-γ) and interleukin-4. These animals had an increasing number of tumor necrosis factor alpha (TNF-α)-producing CD4(+) and CD8(+) T cells than WT CO92-infected mice. These data emphasize the role of TNF-α and IFN-γ in protecting mice against pneumonic plague. Overall, our studies provide evidence that deletion of the lpp and pla genes acts synergistically in protecting animals against pneumonic plague, and we have demonstrated an immunological basis for this protection.
目前,尚无针对鼠疫耶尔森菌(引起腺鼠疫和肺鼠疫的病原体)的 FDA 批准疫苗。由于体液免疫和细胞介导免疫对于宿主提供抗鼠疫保护都是必不可少的,因此我们通过从鼠疫耶尔森氏菌 CO92 中删除 Braun 脂蛋白(lpp)和纤溶酶原激活蛋白酶(pla)基因,开发了一种减毒活疫苗株。Δlpp Δpla 双基因缺失突变株在诱发小鼠腺鼠疫和肺鼠疫方面具有高度减毒作用。此外,通过鼻腔内或皮下途径用突变株免疫的动物在发生继发肺鼠疫方面受到显著保护。在小鼠中,该突变株向周围器官的传播能力较差,同时促炎细胞因子的产生也减少。组织病理学观察到,与野生型(WT)CO92 挑战动物相比,感染 Δlpp Δpla 双突变株的小鼠的肺部和肝脏损伤减轻。与 WT 细菌以及 CO92 特异性抗原相比,Δlpp Δpla 突变株免疫的小鼠诱导了体液免疫反应。此外,与用相同亚致死剂量的 WT CO92 免疫的小鼠相比,用突变株免疫的动物的 T 细胞在体外用热灭活 WT CO92 抗原刺激时表现出更高的增殖反应。同样,来自突变株免疫的小鼠的 T 细胞产生了更多的γ干扰素(IFN-γ)和白细胞介素 4。与 WT CO92 感染的小鼠相比,这些动物产生 TNF-α 的 CD4+和 CD8+T 细胞的数量增加。这些数据强调了 TNF-α和 IFN-γ在保护小鼠免受肺鼠疫中的作用。总的来说,我们的研究结果表明,lpp 和 pla 基因的缺失协同作用可保护动物免受肺鼠疫的侵害,并且我们已经证明了这种保护的免疫学基础。